241 related articles for article (PubMed ID: 25565577)
1. How is national recipient hemovigilance conducted in the United States?
Chung KW; Harvey A; Basavaraju SV; Kuehnert MJ
Transfusion; 2015 Apr; 55(4):703-7. PubMed ID: 25565577
[TBL] [Abstract][Full Text] [Related]
2. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012.
Harvey AR; Basavaraju SV; Chung KW; Kuehnert MJ
Transfusion; 2015 Apr; 55(4):709-18. PubMed ID: 25371300
[TBL] [Abstract][Full Text] [Related]
3. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.
Haass KA; Sapiano MRP; Savinkina A; Kuehnert MJ; Basavaraju SV
Transfus Med Rev; 2019 Apr; 33(2):84-91. PubMed ID: 30930009
[TBL] [Abstract][Full Text] [Related]
4. Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network.
Cumming M; Osinski A; O'Hearn L; Waksmonski P; Herman M; Gordon D; Griffiths E; Knox K; McHale E; Quillen K; Rios J; Pisciotto P; Uhl L; DeMaria A; Andrzejewski C
Transfusion; 2017 Feb; 57(2):478-483. PubMed ID: 27774608
[TBL] [Abstract][Full Text] [Related]
5. Transfusion-related errors and associated adverse reactions and blood product wastage as reported to the National Healthcare Safety Network Hemovigilance Module, 2014-2022.
Chavez Ortiz JL; Griffin I; Kazakova SV; Stewart PB; Kracalik I; Basavaraju SV
Transfusion; 2024 Apr; 64(4):627-637. PubMed ID: 38476028
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the National Healthcare Safety Network Hemovigilance Module for transfusion-related adverse reactions in the United States.
Edens C; Haass KA; Cumming M; Osinski A; O'Hearn L; Passanisi K; Eaton L; Visintainer P; Savinkina A; Kuehnert MJ; Basavaraju SV; Andrzejewski C
Transfusion; 2019 Feb; 59(2):524-533. PubMed ID: 30427540
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018.
Kracalik I; Mowla S; Basavaraju SV; Sapiano MRP
Transfusion; 2021 May; 61(5):1424-1434. PubMed ID: 33880771
[TBL] [Abstract][Full Text] [Related]
8. How do we use the National Healthcare Safety Network for Hemovigilance in Massachusetts?
Iannone A; Cumming M; Osinski A; Brandeburg C; Schultz J; Slider A; Rodrigue B; O'Hearn L; Herman M; McHale E; Rios J; Uhl L; Andrzejewski C; DeMaria A
Transfusion; 2024 Feb; 64(2):200-209. PubMed ID: 38158876
[TBL] [Abstract][Full Text] [Related]
9. Transfusion reaction reporting in the era of hemovigilance: where form meets function.
Dunbar NM; Walsh SJ; Maynard KJ; Szczepiorkowski ZM
Transfusion; 2011 Dec; 51(12):2583-7. PubMed ID: 21745209
[TBL] [Abstract][Full Text] [Related]
10. Hemovigilance in the United States of America.
Menitove JE
Vox Sang; 1998; 74 Suppl 2():447-55. PubMed ID: 9704480
[TBL] [Abstract][Full Text] [Related]
11. AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance Module adverse events definitions protocol.
AuBuchon JP; Fung M; Whitaker B; Malasky J
Transfusion; 2014 Aug; 54(8):2077-83. PubMed ID: 24673261
[TBL] [Abstract][Full Text] [Related]
12. Proposing a Model for the National Hemovigilance Information System in Iran.
Asadi F; Ramezanghorbani N
J Med Life; 2020; 13(2):211-218. PubMed ID: 32742516
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Transfusion-Related Adverse Reactions Among Apheresis Platelets, Whole Blood-Derived Platelets, and Platelets Subjected to Pathogen Reduction Technology as Reported to the National Healthcare Safety Network Hemovigilance Module.
Mowla SJ; Kracalik IT; Sapiano MRP; O'Hearn L; Andrzejewski C; Basavaraju SV
Transfus Med Rev; 2021 Apr; 35(2):78-84. PubMed ID: 33934903
[TBL] [Abstract][Full Text] [Related]
14. [International databases: usefulness and limitations in hemovigilance].
Wiersum-Osselton JC
Transfus Clin Biol; 2010 Dec; 17(5-6):306-9. PubMed ID: 21055991
[TBL] [Abstract][Full Text] [Related]
15. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.
Andreu G; Morel P; Forestier F; Debeir J; Rebibo D; Janvier G; Hervé P
Transfusion; 2002 Oct; 42(10):1356-64. PubMed ID: 12423521
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of the transfusion practitioner.
Miller K; Akers C; Davis AK; Wood E; Hennessy C; Bielby L
Transfus Med Rev; 2015 Apr; 29(2):138-44. PubMed ID: 25634259
[TBL] [Abstract][Full Text] [Related]
17. [Implementation of hemovigilance in Sub-Saharan Africa].
Dahourou H; Tapko JB; Nébié Y; Kiénou K; Sanou M; Diallo M; Barro L; Murphy E; Lefrère JJ
Transfus Clin Biol; 2012 Feb; 19(1):39-45. PubMed ID: 22296906
[TBL] [Abstract][Full Text] [Related]
18. Delayed hemolytic transfusion reaction in the French hemovigilance system.
Rieux C; Brittenham G; Bachir D; De Meyer E; Boudjedir K;
Transfus Clin Biol; 2019 May; 26(2):109-111. PubMed ID: 30910456
[TBL] [Abstract][Full Text] [Related]
19. The Quebec hemovigilance system: description and results from the first two years.
Robillard P; Nawej KI; Jochem K
Transfus Apher Sci; 2004 Oct; 31(2):111-22. PubMed ID: 15501415
[TBL] [Abstract][Full Text] [Related]
20. Impact of the early coronavirus disease 2019 pandemic on blood utilization in the United States: A time-series analysis of data reported to the National Healthcare Safety Network Hemovigilance Module.
Kracalik I; Mowla S; Katz L; Cumming M; Sapiano MRP; Basavaraju SV
Transfusion; 2021 Sep; 61 Suppl 2(Suppl 2):S36-S43. PubMed ID: 33990963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
